Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 28 2025
0mins
Source: Newsfilter
Acquisition Announcement: Supernus Pharmaceuticals has announced the expiration of the waiting period under the HSR Act for its proposed acquisition of Sage Therapeutics, which is set to be completed through a tender offer and subsequent merger.
Offer Details: The tender offer includes a payment of $8.50 per share in cash plus contingent value rights that could yield up to an additional $3.50 per share based on specific sales milestones related to the drug ZURZUVAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
